Chemotherapy-induced Peripheral Neuropathy Treatment Market Poised for Strong Growth Throughout the Forecast Period (2025–2034) Amid Rising Chemotherapy Adoption | DelveInsight [Yahoo! Fin...
Dogwood Therapeutics, Inc. (DWTX)
Company Research
Source: Yahoo! Finance
The chemotherapy-induced peripheral neuropathy market is emerging as a high-value market opportunity driven by the lack of approved therapies and the significant unmet clinical need. Rising global chemotherapy usage, especially with neurotoxic agents, continues to expand the patient pool. Additionally, the launch of emerging therapies such as Halneuron (Wex Pharmaceuticals), ATX01 (AlgoTx), ART-123 (Asahi Kasei Pharma/Veloxis Pharmaceuticals), WST-057 (WinSanTor, Inc.), and others will further fuel the CIPN market growth.
Show less
Read more
Impact Snapshot
Event Time:
DWTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DWTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DWTX alerts
High impacting Dogwood Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DWTX
News
- Dogwood Therapeutics Reports Third Quarter 2025 Financial ResultsGlobeNewswire
- Dogwood Therapeutics (NASDAQ:DWTX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit [Yahoo! Finance]Yahoo! Finance
- Dogwood Therapeutics (NASDAQ:DWTX) had its price target raised by analysts at HC Wainwright from $10.00 to $12.00. They now have a "buy" rating on the stock.MarketBeat
- Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients [YY
DWTX
Earnings
- 11/6/25 - Miss
DWTX
Sec Filings
- 12/5/25 - Form 4
- 12/5/25 - Form 4
- 12/5/25 - Form 4
- DWTX's page on the SEC website